Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jagadeesh Aluri

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
ACS Omega|September 8, 2025
An LC-MS/MS Assay of Irsenontrine, a Novel Phosphodiesterase‑9 Inhibitor, in Human Plasma, Urine and Cerebrospinal Fluid for Application to Clinical Pharmacokinetic StudiesKoichiro Hotta, Karolina Doda, Jagadeesh Aluri, et al.
Clinical Pharmacology in Drug Development|March 25, 2017
Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, Safety, and Tolerability of Avatrombopag in Healthy Japanese and White SubjectsMaiko Nomoto, Gina Pastino, Bhaskar Rege, et al.
Journal of Clinical Pharmacology|July 16, 2020
Population Pharmacokinetics and Exposure-Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia DisorderBojan Lalovic, Oneeb Majid, Jagadeesh Aluri, et al.
Journal of Clinical Pharmacology|September 11, 2014
Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administrationRobert Shumaker, Jagadeesh Aluri, Jean Fan, et al.
International Journal of Clinical Pharmacology and Therapeutics|January 21, 2015
A randomized, three-treatment, three-period, six-sequence-crossover, single-center, bioequivalence study to evaluate the impact of different 10-mg crystalline forms on the pharmacokinetics of lenvatinib in healthy volunteersLucy Lee, Pina D'Angelo, David Verbel, et al.
International Journal of Clinical Pharmacology and Therapeutics|February 20, 2014
Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteersRobert Shumaker, Jagadeesh Aluri, Jean Fan, et al.
Clinical Pharmacology in Drug Development|May 21, 2022
Intravenous Perampanel as an Interchangeable Alternative to Oral Perampanel: A Randomized, Crossover, Phase I Pharmacokinetic and Safety StudyZiad Hussein, Oneeb Majid, Peter Boyd, et al.
European Journal of Drug Metabolism and Pharmacokinetics|February 19, 2020
An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Patients with Advanced Solid TumorsRobert Shumaker, Min Ren, Jagadeesh Aluri, et al.
Clinical Pharmacology in Drug Development|June 23, 2015
Effects of Ketoconazole on the Pharmacokinetics of Lenvatinib (E7080) in Healthy ParticipantsRobert Shumaker, Jagadeesh Aluri, Jean Fan, et al.
British Journal of Clinical Pharmacology|August 11, 2023
Lemborexant levels in breast milk after single doses in healthy, lactating womenSumit Rawal, Darin Brimhall, Jagadeesh Aluri, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
ACS Omega|September 8, 2025
An LC-MS/MS Assay of Irsenontrine, a Novel Phosphodiesterase‑9 Inhibitor, in Human Plasma, Urine and Cerebrospinal Fluid for Application to Clinical Pharmacokinetic StudiesKoichiro Hotta, Karolina Doda, Jagadeesh Aluri, et al.
Clinical Pharmacology in Drug Development|March 25, 2017
Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, Safety, and Tolerability of Avatrombopag in Healthy Japanese and White SubjectsMaiko Nomoto, Gina Pastino, Bhaskar Rege, et al.
Journal of Clinical Pharmacology|July 16, 2020
Population Pharmacokinetics and Exposure-Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia DisorderBojan Lalovic, Oneeb Majid, Jagadeesh Aluri, et al.
Journal of Clinical Pharmacology|September 11, 2014
Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administrationRobert Shumaker, Jagadeesh Aluri, Jean Fan, et al.
International Journal of Clinical Pharmacology and Therapeutics|January 21, 2015
A randomized, three-treatment, three-period, six-sequence-crossover, single-center, bioequivalence study to evaluate the impact of different 10-mg crystalline forms on the pharmacokinetics of lenvatinib in healthy volunteersLucy Lee, Pina D'Angelo, David Verbel, et al.
International Journal of Clinical Pharmacology and Therapeutics|February 20, 2014
Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteersRobert Shumaker, Jagadeesh Aluri, Jean Fan, et al.
Clinical Pharmacology in Drug Development|May 21, 2022
Intravenous Perampanel as an Interchangeable Alternative to Oral Perampanel: A Randomized, Crossover, Phase I Pharmacokinetic and Safety StudyZiad Hussein, Oneeb Majid, Peter Boyd, et al.
European Journal of Drug Metabolism and Pharmacokinetics|February 19, 2020
An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Patients with Advanced Solid TumorsRobert Shumaker, Min Ren, Jagadeesh Aluri, et al.
Clinical Pharmacology in Drug Development|June 23, 2015
Effects of Ketoconazole on the Pharmacokinetics of Lenvatinib (E7080) in Healthy ParticipantsRobert Shumaker, Jagadeesh Aluri, Jean Fan, et al.
British Journal of Clinical Pharmacology|August 11, 2023
Lemborexant levels in breast milk after single doses in healthy, lactating womenSumit Rawal, Darin Brimhall, Jagadeesh Aluri, et al.
Pageof 4